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Isopropylantipyrine (IPA, propyphenazone) is a pyrazolone derivative, widely used
as an antipyretic and analgesic drug. The aim of the study was to evaluate the
influence of propyphenazone on rat development. IPA was administered to preg-
nant rats from day 8 to day 14 of pregnancy once a day, orally by a stomach
tube at doses of 2.10 (R1), 21.0 (R2), and 210.0 mg/kg/day (R3). The dams were
sacrificed on day 21 of gestation and corpora luteum, implants, resorptions, and
live foetuses were counted. The weight of foetuses and placentas, the length of
foetuses and their tails were checked. The foetuses were fixed in alcohol and
skeletons were stained with alizarin. There was a statistical difference in body
length in R1, R2 and numbers of subcutaneous ecchymose in R1. External and
skeletal examination of the foetuses revealed no evidence of teratogenesis.
It can be concluded that IPA has no harmful effects on the prenatal develop-
ment of the rat offspring at doses used in the present study.
key words: isopropylantipyrine, propyphenazone, teratogen, congeni-
tal-malformation, pregnancy, rat
INTRODUCTION
Embryotoxicity and teratogenicity are side effects
that complicated therapy with various drugs during
pregnancy. These side effects can occur in high dos-
es  close to the toxic level for the mother. Howev-
er, some of the medicines have selective develop-
ment toxicity in doses that are well tolerated by the
mother [3,10,13]. Amniopterin was the first known
drug, which interferes with normal pregnancy [16].
This finding was unimportant until 1959 when Ger-
man and Australian clinicians became aware of the
epidemic of phocomelia. Epidemiological and exper-
imental studies showed that this unusual limb re-
duction defect was caused by thalidomide  the
drug, which was marketed as safe, even when taken
in overdose [3,10].
Responding to public pressure the toxicologists
of the World Health Organization (WHO) held a
meeting in Geneva from 14 to 19 November 1966
to develop guidelines for evaluating drug safety and
the subsequent extrapolation of animal data to man
[18]. The WHO principles published after the meet-
ing, as well as the law in associated countries, stat-
ed that each new drug be evaluated for its prenatal
toxic effects. However, older drugs on the market
did not need these studies [7,18]. As a consequence
many widely used xenobiotics are still in use with-
out teratology data.
One of these substances is isopropylantipyrine (IPA,
propyphenazone, propyfenazone(a), 2,3-dimethyl-1-
phenyl-4-isopropyl-pyrazolin-5-one, CAS 479925)
 a popular analgesic and antipyretic medicine,
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which has been produced in the Roche laboratory
since 1933, and later by other pharmaceutical com-
panies. Until 1977 it had been used as a monosub-
stance with an annual world-wide consumption ex-
ceeding 100 tons. Subsequently consumption rose
dramatically when European authorities mandated
the replacement of aminophenazone by IPA in com-
bination analgesics [1,8].
To the best of my knowledge, for almost 70 years
no one published data regarding prenatal effects of
IPA except for the short conclusion of the compa-
nys study in IPA Product Monograph [8].
This study was taken up to evaluate prenatal tox-
icity of IPA, particularly any influence on bone con-
genital malformations in single alizarin-stained spec-
imens, which is a sensitive and widely used marker
in teratological studies.
MATERIAL AND METHODS
This experiment was based on an animal experimen-
tal model designed according to the standards and
principles of WHO and the guidelines of the Bioeth-
ical Committee of the Medical University School of
Lublin, Poland [9,17,18].
The experiment was conducted on Wistar breed
rats, originally obtained from a commercial breeder
(Warszawa-Rembertów, Poland), with initial body
weight of 180 – 15 grams. The animals were housed
in standard laboratory cages (maximum of 5 rats per
cage) at a room temperature of 20 – 3°C on a day-
light cycle (7 A.M.7 P.M.). Standard laboratory fod-
der (Motycz, Poland) and tap water were provided
ad libitum. Food and water consumption were mon-
itored daily.
Virgin females after two weeks of acclimatisa-
tion period were mated overnight with males of the
same stock. The presence of a vaginal plug or sperm
in the vaginal smear examined the following morn-
ing was taken to indicate successful mating and the
day was considered the first day of gestation. The
inseminated animals were randomly placed in ex-
perimental or control groups with a minimum of 12
in each group. Some females were not pregnant
despite the presence of spermatozoa in the smear.
Isopropylantipyrine  IPA (Hoechst, Germany;
99.4% purity) was ground with Tween 80 (Sigma,
Germany) and then diluted in distilled water. The
suspension was administered orally with the use of
a stomach tube, once daily between 7.30 A.M. and
8 A.M., on days 814 of gestation. The tested sub-
stance was given in three different doses: R1  2.1
mg/kg body weight (p = 7  number of pregnant
female; f = 104  number of foetuses; s = 74 
number of examined alizarin staining specimens), R2
 21.0 mg/kg b.w. (p = 11, f = 158, s = 119), and
R3  210.0 mg/kg b.w. (p = 7, f = 97, s = 56). The
volumes that were given were proportionate to the
body weight of the animals, e.g., 10 ml/kg b.w.
Two control groups were designed: T  the fe-
males received the Tween 80 solution during the
whole second trimester of pregnancy (p = 10, f =
148, s = 118), K  untreated control (p = 19, f =
275, s = 176). The animals in group T received Tween
80 water suspension in volumes corresponding to
those given in the treatment groups. The body weight
gain of the dams was monitored on days 1, 8, 14,
and 21 of pregnancy.
All the animals were killed by decapitation on the
21st day of gestation, and the uteri were delivered
by laparotomy. The corpora lutea, implants, resorp-
tions, and the live and dead foetuses were counted.
Foetuses were removed, separated from placenta and
examined macroscopically for external malforma-
tions. The weight of foetuses and placentas, the
lengths of foetuses and their tails were checked. The
pre- and postimplantation mortality factors were
calculated.
At least 2/3 of the foetuses from each litter were
fixed in 95% ethanol for the study of the skeleton by
single alizarin red S staining and examined under
a stereo-dissection microscope.
Data were statistically analysed using Mann-Whit-
ney test and followed by ANOVA [14]. The level of
significance was set at p < 0.05 (a = 0.05).
RESULTS
During the whole experiment, no maternal deaths
and behavioural changes were recorded in any group.
The drug-treated females consumed as much food
and water as the controls and gained comparable
weight. There were no signs of maternal toxicity due
to IPA treatment (data not shown).
Since there were no statistical differences in foe-
tal parameters between both control groups (T, K),
they were united in one pooled control group (CON)
to minimise observation error [2].
The number of corpora luteum, foetuses and re-
sorptions did not exhibit any significant difference
compared with the pooled control group. This re-
sulted in insignificant differences in the preimplan-
tation and postimplantation mortality factors (Tab. 1).
The body weight of the foetuses and the weight of
placentas from the IPA-treated groups were lower
than the ones in the pooled control group but with-
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out any statistical correlation. A significant decrease
in the length of foetuses was found in the groups
R1 and R2, when compared with the control group.
The decrease in this parameter with the highest dose
did not cause significant alterations. The mean tail
length was not statistically different.
The external malformations were not noted in
drug-treated and control groups except for subcu-
taneous haematomas which were found in parietal
region (K), left auricular cochlea (R3), buccal region
(R3), left triangle of the neck (R2, R3), right triangle
of the neck (R2), collar-shaped haematoma of the
neck (R2), interscapular region (R1, 2x R2, R3), right
inguinal region (R3), sacral region (R1), left leg (K, T,
R1), left calcaneal region (R1, R2) and on the mobile
part of the tail (K). The analysis of their numbers
revealed a marginal significant increase only in the
group R1, when compared with the pooled control
group (Fig. 1).
Table 2 summarises the frequency and types of
bone malformations observed in examined groups.
The statistical examination showed insignificant dif-
ferences between pooled control and IPA-treated
groups.
The examination of 249 skeletons of IPA-ex-
posed foetuses and 294 from both control groups
showed a partial ossification of the frontal, pari-
etal, interparietal, supraoccipital bones. In one of
the foetuses from the R3 group, the interparietal
bone was missing. The other bones of the skull,
including basicranial ones, did not show any mal-
formation (Fig. 2).
The missing hyoid bone was observed in one spec-
imen from R1 group and in one specimen from R3
group. The reduction of alizarin staining of the hy-
oid bone was found in all experimental and controls
groups.
The bilateral wavy thoracic ribs were found in only
two specimens from group R2. Both foetuses came
from the same litter. In one foetus the wavy ribs co-
existed with bilateral, asymmetrical, multilevel reduc-
tion of vertebrae ossification (Fig. 3). The individual
cases of the short 13th ribs were noted only in both
control groups. The wavy 13th ribs were observed
occasionally in all examined groups. The bud unilat-
eral extra lumbar ribs (L1) were observed in all IPA-
exposed and untreated control groups. The bilateral
bud lumbar ribs, on the level L1, were observed only
in one specimen of the foetuses exposed in-utero to
the middle dose of IPA. The unilateral short L1 ribs
were observed in the groups R1 and R2 as well as in
one case in untreated control groups.
Table 1. Tested foetal development parameters in isopropylantipyrine-treated (R) and pooled control groups (CON)
CON R1 R2 R3
MD – SD MD – SD MD – SD MD – SD
Foetal weight [g] 3.80 – 0.42 3.64 – 0.080 3.74 – 0.300 3.56 – 0.23
Foetal length [mm] 38.55 – 1.09 36.87 – 0.32* 37.54 – 1.10* 38.12 – 0.96
Tail length [mm] 11.85 – 0.52 11.80 – 0.230 11,67 – 0.280 11.74 – 0.35
Placenta weight [g] 0.59 – 0.06 0.57 – 0.050 0.57 – 0.040 0.56 – 0.02
Number of corpora lutea 15.13 – 0.43 15.57 – 2.070 15.09 – 1.700 14.66 – 0.51
Number of foetuses 14.31 – 2.25 14.85 – 2.410 14.36 – 2.610 13.83 – 1.16
Number of resorptions 0.55 – 0.68 0.42 – 0.530 0.36 – 0.800 0.50 – 0.54
Preimplantation mortality 2.08 – 4.37 2.02 – 3.270 2.86 – 5.200 2.30 – 3.25
Postimplantation mortality 3.40 – 4.19 2.85 – 3.400 2.89 – 6.370 3.58 – 3.59
Number of subcutaneous haematomas 0.20 – 0.41 1.00 – 0.810 0.63 – 0.920 1.00 – 1.59
MD  mean deviation, SD  standard deviation, *  differ significantly (p < 0.05) vs pooled control value
Figure 1. Incidence of subcutaneous haematomas in isopropy-
lantipyrine-treated (R) and pooled control groups (CON).
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Unilateral absence of the 4th metacarpal bone was
observed in the R1, R2 and pooled control groups.
Bilateral absence of one metacarpal bone was found
in all examined groups. One foetus from group R3
had bilateral missing of the 1st and the 4th metacar-
Table 2. Incidence of skeletal variations (%) in isopropylantipyrine-treated (R) and pooled control groups (CON)
CON R1 R2 R3
Number of examined alizarin staining specimens 294 74 119 56
Frontal, reduced ossification   2 (1.68) 1 (1.78)
Parietal, reduced ossification 19 (6.46) 6 (8.11) 12 (10.08) 8 (14,28)
Interparietal, missing    1 (1.78)
Interparietal, reduced ossification 22 (7.48) 7 (9.45) 16 (13.44) 8 (14.28)
Supraoccipital, reduced ossification 10 (3.40) 5 (6.75) 9 (7.56) 5 (8.92)
Hyoid, missing  1 (1.35)  1 (1.78)
Hyoid, reduced ossification 2 (0.68) 1 (1.35) 3 (2.52) 2 (3.57)
Vertebral arches, multilevel reduced ossification   1 (0.84) 
Wave ribs   2 (1.68) 
13th rib, wavy 7 (2.38) 1 (1.35) 4 (3.36) 1 (1.78)
13th rib, unilateral short 2 (0.68)   
Supernumerary rib, bud unilateral (L1) 1 (0.34) 2 (2.70) 1 (0.84) 1 (1.78)
Supernumerary rib, bud bilateral (L1)   1 (0.84) 
Supernumerary rib, short unilateral (L1) 1 (0.34) 1 (1.35) 1 (0.84) 
Metacarpal, unilateral missing of one bone 3 (1.02) 1 (1.35) 1 (0.84) 
Metacarpal, bilateral missing of one bone 4 (1.36) 3 (4.05) 3 (2.54) 4 (7.14)
Metacarpal, unilateral missing of two bones    1 (1.78)
Metatarsal, unilateral missing of two bones 10 (3.40) 5 (6.75) 8 (6.72) 6 (10.71)
Metatarsal, bilateral missing of two bones   1 (0.84) 
6th sternebrae, missing 2 (0.68)  3 (2.54) 1 (1.78)
6th sternebrae, rudimentary 4 (1.36) 2 (2.70) 3 (2.52) 2 (3.57)
6th sternebrae, cleaved 1 (0.34)   
6th sternebrae, bifurcated at distal end 1 (0.34)  2 (1.68) 
6th sternebrae, reduced ossification 20 (6.80) 6 (8.10) 10 (8.40) 4 (7.14)
5th sternebrae, missing 1 (0.34) 1 (1.35) 3 (2.52) 2 (3.57)
5th sternebrae, rudimentary 21 (7.14) 2 (2.70) 8 (6.72)  4 (7.14)
5th sternebrae, dumbbell-shaped 14 (4.76) 3 (4.05) 6 (5.04) 1 (1.78)
5th sternebrae, reduced ossification 3 (1.02) 4 (5.40) 2 (1.68) 1 (1.78)
4th sternebrae, missing  1 (1.35)  
4th sternebrae, rudimentary 2 (0.68)  1 (0.84) 1 (1.78)
3rd sternebrae, rudimentary   1 (0.84) 2 (3.57)
2nd sternebrae, missing  1 (1.35)  
2nd sternebrae, cleaved    1 (1.78)
1st sternebrae, cleaved    1 (1.78)
1st sternebrae, reduced ossification 1 (0.34)   2 (3.57)
pal bones. The 5th metatarsal bone was not observed
in a few foetuses from all examined groups. Bilater-
al missing of two metatarsal bones was found only
in one foetus exposed prenatally to the middle dos-
es of IPA. Also present were wavy ribs and bilateral
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missing of one metacarpal bone and poorly ossified
phalanges (Fig. 3).
The 5th and/or 6th sternebrae was the most com-
mon malformed part of the sternum. Anomalies of
the other four sternebraes were seen occasionally.
The missing, rudimentary, and poorly ossified sterne-
brae were the most common anomalies. The other
malformations such as dumbbell-shaping and bifur-
cating were seen in the control and IPA-treated
groups. Cleavage of the 6th sternebrae was found in
only one specimen from the untreated control group.
DISCUSSION
The results of this study show that the tested IPA did
not cause any external and skeleton malformations
and only slightly changed the foetal parameters.
The body weight, the length of the foetuses and
their tails are considered sensitive indicators of an
animals response to xenobiotics [6,9]. A significant
decrease in body length, which was observed in
groups R1 and R2, was not confirmed in group R3
 exposed to the highest dose of IPA. Knowing that
other parameters were not statistically different, the
changes can be interpreted as occasional.
An increased number of subcutaneous haemato-
mas that occurred in group R1, can be interpreted
as a side effect of inhibition of cycolooxygenase and
block in synthesis of thromboxan [1]. This finding as
well as the decreasing of the body weight was not
confirmed in the highest dose-group.
In the previous test, IPA administered at doses
30.0, 150.0, 300.0, 450.0 mg/kg b.w./day from day
9 until day 14 of rat pregnancy did not cause any
development side effects [8]. Only a slight inhibition
of the body weight gain was observed in the high-
est dose group compared with the control one. Those
results come from the conclusion of the teratologi-
cal study published as a short note in IPA Product
Monograph [8]. However, the author did not explain
the methods used to verify this conclusion.
The spectrum and frequency of bone malforma-
tion presented in this study are similar to results
observed in foetuses exposed prenatally to caffeine
in doses 0.770.0 mg/kg b.w. and to paracetamol in
doses 3.5350.0 mg/kg b.w. [2,4,5]. Only the wavy
ribs found in two foetuses, and poorly ossified arch-
es of vertebras, together with metacarpal and meta-
tarsal missing in one of them, were related only to
IPA. The other malformations were seen in caffeine
 as well as paracetamol-exposed foetuses. Those
results are fully comparably since the same method-
ology, was used for testing all three substances. It
was shown that caffeine and paracetamol did not
disturb the rats skeleton development [2,4]. IPA was
even better tolerated than paracetamol which low-
ered the foetal body weight and length, and was as
Figure 3. Skeleton of rat foetus of gestation day 21 in alizarin
red-S staining. Bilateral wavy ribs, and poorly ossified 7th, 9th,
10th, 11th, 12th, 13th thoracic vertebral arches on the left side; 6th,
8th, 12th, 13th thoracic vertebral arches on the right side, and 1st,
4th, 5th lumbar left vertebral arches. Bilateral missing of metacar-
pal bone, and poorly ossified phalanges.
Figure 2. Well-formed skeleton of rat foetus on gestation day 21
in alizarin red-S staining.
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well tolerated as the experimental doses of caffeine.
However, due to different chemical structure, mech-
anism of action, and metabolic pathways of caffeine,
paracetamol and IPA this kind of analysis is purely
theoretical [1,8,11,12].
Although there are difficulties in extrapolating
the above results to humans, they do not suggest
an influence of IPA on developing organisms. It was
not possible to find any other publications describ-
ing the influence of IPA on the foetal development
or the side effects of its administration on pregnant
organisms. Accordingly, larger epidemiological and
subsequent animal studies using other laboratory
animals are needed to evaluate the potential influ-
ence of IPA on human development.
In conclusion it could be stressed that isopropy-
lantipyrine administered for the whole second tri-
mester of pregnancy did not cause embryotoxic ef-
fect and that no harmful effects of isopropylantipy-
rine at doses used in the present study on rats
skeleton development were observed.
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